Neurological Disorder Treatment

Search documents
Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery
GlobeNewswire News Room· 2025-04-30 05:00
Ad Hoc Announcement Pursuant to Art. 53 LR Functional recovery following stroke relies on the formation of new or reactivation of existing neural connections. Accumulating evidence suggests that the mGlu5 receptor modulates brain plasticity and function. A paper published in BRAIN*, titled "Inhibiting metabotropic glutamate receptor 5 after stroke restores brain function and connectivity", showed that daily treatment with mGlu5 NAMs for 12 days, starting 2 or 10 days after stroke, restored lost somatosensor ...
NeuroOne® Issues Letter to Shareholders
Newsfilter· 2025-04-16 13:00
Company Now Fully Funded Through at least Fiscal 2026; Company Confirms No Material Impact from Global Tariffs EDEN PRAIRIE, Minn., April 16, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has issued a letter to shareholders from CEO, Dave Rosa. Dear Shareholders, In recent months, NeuroOne has achieved sever ...